There has been little support for dopamine agonists, such as bromocriptine and levodopa in the treatment of post-stroke aphasia; however, future research taking genetics into consideration, specifically BDNF polymorphisms may assist with matching patients who may be more or less responsive. The gene discussed is BDNF; the disease is Aphasia.